Form 4: ImmunityBio Chief Accounting Officer Reports Stock Transactions Following RSU Vesting

ImmunityBio's Chief Accounting Officer, Regan J. Lauer, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Regan J. Lauer, Chief Accounting Officer of ImmunityBio, Inc., filed a Form 4 detailing changes in beneficial ownership of company stock.
• On December 15, 2024, 21,031 restricted stock units (RSUs) vested, converting into common stock.
• Simultaneously, 7,503 shares were sold at $2.87 per share to cover tax obligations related to the vesting.
• Following these transactions, Lauer directly owns 107,862 shares of ImmunityBio common stock.
• The RSUs vested in three equal tranches: June 15, 2023, December 15, 2023, and December 15, 2024.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company officer, which is common practice in publicly traded companies. It provides transparency into the ownership changes of company stock by insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The vesting schedule of the RSUs is a common practice for employee equity compensation.
• The sale of shares to cover tax obligations is a typical occurrence when RSUs vest.

Stakeholder Impact

• The transaction has a minor impact on the total outstanding shares of ImmunityBio.
• The sale of shares by an officer is a normal part of equity compensation and is not expected to have a significant impact on the stock price.

Key Dates

Keywords

Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, RSU, ImmunityBio, IBRX, Stock Vesting, Chief Accounting Officer